If their Biosensor receives approval you won't be disappointed:
Biophage announces the capability of its PDS(R) Biosensor to rapidly detect Harmful properties of metals on living cells
08:41 EST Tuesday, November 28, 2006
EPA decision opens new markets in environmental risk assessment
MONTREAL, Nov. 28 /CNW Telbec/ - Biophage Pharma Inc. (TSX.V: BUG) today announced that its PDS(R) Biosensor has the ability to rapidly detect the harmful properties of metals on living cells (cytotoxicity).
A recent article published in the Washington Post (Nov 23, 2006) announced that the EPA will begin regulating a large class of Nanoproducts sold as germ-killing mainly because they may pose unanticipated environmental risks.
"Measuring cytotoxic effects enables quantitative measurements of such risks. We believe our PDS(R) Biosensor responds to this need and will help EPA and manufacturers assess the potential harmful effects of certain classes of metals on living cells of human, animal or plant origin," stated Dr. Rosemonde Mandeville, President and CEO of Biophage Pharma Inc.
"Conventional materials, such as carbon, silver or gold, exhibit unconventional properties when manufactured on a nanoscale. This is largely because the nanoparticles have relatively large surface areas for their small mass, and the exposed atoms have increased chemical reactivity that could induce potential adverse effects measurable by cytotoxicity test." Dr. Mandeville explained."
"We have demonstrated that our Biosensor can rapidly detect (in less than 1h) the harmful effects of certain toxic metals like mercury and cadmium on mammalian cells. These solid proof-of-concept results open completely new markets for our biosensors in environmental risk assessment," stated Dr. Rosemonde Mandeville, adding "The new PDS(R) Biosensor is being extensively tested and patents are to be filed in the first quarter of 2007. This new diagnostic tool is a paradigm leap in the diagnostic domain and the Company expects it to contribute significant revenues and income," concluded Dr. Mandeville.
About Biophage Pharma Inc.
Biophage Pharma is a growth company focused on the development of innovative phage-based products and technologies for the detection and management of bacterial contaminations. Founded in 1995, Biophage operates three divisions: (1) The phage therapy division for the management of bacterial contaminations in the medical, veterinary and environment fields; (2) The Biosensors division for the development and commercialization of Biosensors, and more particularly a portable PDS(R) Biosensor which is entering in the pre-commercialization stage; (3) The Immunotox Labs division which provides services in Immunogenicity and Immunotoxicity, Nanotoxicity and Ecotoxicology, Beryllium sensitivity testing and MELISA(R) testing for the detection of sensitization to more than 200 different allergens including a large number of metals, penicillin, gluten and pollens. (www.biophagepharma.com ; www.immunotoxlabs.com ).
The TSX Venture Exchange does not accept responsibility for the adequacy
News 
Market Data 
Discover 
